Abstract: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib, have been demonstrated to effectively treat the patients of extracranial non-small cell lung cancer (NSCLC). However, these patients often develop brain metastasis (BM) during their disease course. The major obstacle to treat BM is the limited penetration of anticancer drugs across the blood-brain barrier (BBB). In the present study, we utilized gefitinib-loaded liposomes with different modifications to improve gefitinib delivery across the in vitro BBB model of bEnd.3 cells. Gefitinib was encapsulated in small unilamellar liposomes modified with glutathione (GSH) and Tween 80 (SUV-G+T; one ligand plus one surfactant) or RF (SUV-RF; one α-helical cell-penetrating peptide). GSH, Tween 80, and RF were tested by the sulforhodamine B (SRB) assay to find their non-cytotoxic concentrations on bEnd.3 cells. The enhancement on gefitinib across the BBB was evaluated by cytotoxicity assay on human lung adenocarcinoma PC9 cells under the bEnd.3 cells grown on the transwell inserts. Our findings showed that gefitinib incorporated in SUV-G+T or SUV-RF across the bEnd.3 cells significantly reduced the viability of PC9 cells more than that of free gefitinib. Furthermore, SUV-RF showed no cytotoxicity on bEnd.3 cells and did not affect the transendothelial electrical resistance (TEER) and transendothelial permeability of sodium fluorescein across the BBB model. Moreover, flow cytometry and confocal laser scanning microscopy were employed to evaluate the endocytosis pathways of SUV-RF. The results indicated that the uptake into bEnd.3 cells was mainly through adsorptive-mediated mechanism via electrostatic interaction and partially through clathrin-mediated endocytosis. In conclusion, cell penetrating peptide-conjugated SUV-RF shed light on improving drug transport across the BBB via modulating the transcytosis pathway(s).
Introduction
Non-small cell lung cancer (NSCLC) is one of the most common cancer types in the world. Current epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) treatment, including gefitinib and afatinib, are highly effective to extracranial lung cancer patients with specific EGFR mutations [1] . Despite this, the major cause of death from lung cancer is due to metastases that are Polymeric nanoparticles modified with surfactants, such as polysorbates, have been demonstrated to help the particles permeate across the BBB [16] and improve brain targeting potential for nanoparticles [17] . Modification of nanoparticles with polysorbate 80 (Tween 80) has been reported to cross the BBB by enhancing the plasma adsorption of apolipoproteins, such as apolipoprotein E (ApoE) or B (ApoB), on the nanoparticle surface and thus enabling them to interact with the low density lipoproteins (LDL) receptor [18] . Such coating may enhance the nanoparticles internalization via receptor mediated endocytosis by brain endothelial cells [18, 19] . In addition, since polysorbate 80 is also a P-gp modulator, it has been reported that nanoparticle coated with polysorbate 80 may escape the efflux by the P-gp transporter, and thus improving brain capillary endothelial cell uptake of nanoparticles [19, 20] . In this study, liposomes are prepared with surface modification by GSH and/or Tween 80 to evaluate their BBB penetration and cytotoxicity on human lung adenocarcinoma PC-9 cells.
Furthermore, our second approach is to use liposomes conjugated with RF, one cell-penetrating peptide (CPP). Surface modulation of nanoparticles with CPPs assisted in endosomal escape and expedited their cellular internalization [21] . CPPs have multiple choice in sequence design [22] . A traditional CPP, the trans-activator of transcription (TAT) of HIV-1, has been extensively conjugated on the surface of drug-loaded nanoparticles to increase the transport efficiency across the BBB to the CNS [23] . However, drawbacks of TAT include non-human origin, immunogenicity, and low delivery efficiency [24] . Recent studies have explored a new CPP called RF from screening of the 16 amino acid peptide library [25] [26] [27] [28] . The RF peptide has a α-helical structure with a high normal cell compatibility, similar cell penetrating and cancer cell death activities compared with those of TAT [25, 27] . Additionally, RF showed a better cell selectivity than that of TAT. It showed lower uptake into 3T3-L1 cells, but higher uptake into human alveolar epithelial adenocarcinoma A549 cells and human cervical cancer HeLa cells [25] . This peptide was internalized via endocytosis, then surrounded inside endosomes or lysosomes, escaped from endosome, and consequently distributed around the nucleus [25] . Thus, RF possesses the potential to be conjugated into a delivery system with the advantages of high efficiency, low toxicity, and cell selectivity [25, 28] . In this study, TAT was also evaluated for comparison. Based on the above understanding, we thus aim to utilize gefitinib-encapsulated PEGylated liposomes, which were surface modified with GSH and/or polysorbate 80 or conjugated to RF for enhancing gefitinib across the bEnd3 cells to exhibit their cytotoxicity on PC9.
Results

Determination of Encapsulation Efficiency (EE)%, Particle Size, and ζ Potential of PEGylated Liposomal Gefitinib
Characteristics of PEGylated liposomes modified with GSH, Tween 80, GSH plus Tween 80, and RF were summarized in Table 1 . A schematic graph displaying the formation of PEGylated liposomes conjugated with RF peptide is shown in Figure 1A . These liposomal preparations with or without modification were well-dispersed nanoparticles with sizes changed from 85.8 ± 3.7 nm for SUV-T (SUV-Tween 80) to 147.1 ± 3.9 nm for SUV-RF (Figure 1B,C; Table 1) , with a polydispersity index about 0.1 ( Table 1 ). The mean zeta potential of liposomes was ranged from −3.82 ± 0.85 to −1.70 ± 0.16 mV (n = 3; Table 1 ). The morphology of these liposomal dispersions was observed by transmission electron microscope (TEM). As demonstrated in Figure 1D , this population of liposomes SUV-RF displayed a diameter around 100 nm. These nanoparticles were close to spherical in shape ( Figure 1D ). Encapsulation efficiency (EE)% of these PEGylated liposomes was 86.70% ± 2.75%. 
In Vitro Release of Gefitinib from Small Unilamellar Vesicle (SUV)
The in vitro release experiments of gefitinib alone and gefitinib in SUV-Mal or conjugated with RF were investigated using a dynamic release assay under sink conditions, as shown in Figure 2 . The assay was carried out via dialysis using a regenerated cellulose dialysis membrane with an initial gefitinib concentration of 20 µM, in 500 mL of phosphate-buffered saline (PBS) with 2% Tween 80 at 37 °C for 24 h. We found that a higher release percent from gefitinib alone was monitored in the initial phase compared with the gefitinib release from the SUV-Mal or SUV-RF ( Figure 2 ). It was observed that 86.49% ± 3.54% of the amount of gefitinib was released after 1 h when compared with 24.86% ± 1.84% of gefitinib release for SUV-RF (Figure 2) . After 24 h, the amount of gefitinib released from SUV-RF is 84.37% ± 1.97%, in contrast to 97.21% ± 5.65% of gefitinib being released in its free form ( Figure 2 ). 
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The Blood-Brain Barrier (BBB) Barrier Integrity
The in vitro BBB model was constructed using bEnd.3 cells grown on Transwell inserts of 0.4 µm pore size ( Figure 3A) . Morphology of the BBB model was observed by staining bEnd.3 cells with crystal violet and cell image was captured under a Nikon inverted tissue culture microscope ( Figure 3B ). The bEnd.3 cells exhibited dense, uniform, and intact monolayer characteristics. The BBB barrier integrity was evaluated by TEER measurement and permeability study ( Figure 3C,D) . After seeding bEnd.3 cells on inserts for two days, TEER was 91.07 ± 5.08 Ω·cm 2 ( Figure 3C ). After four-day culture, TEER reached 138.01 ± 9.70 Ω·cm 2 , which represented these monolayers were ready for the following experiments as a BBB model ( Figure 3C ). Consistently, the previous report also used the TEER value above 130 Ω·cm 2 for their BBB model [29] . Furthermore, permeability percent of FITC-dextran (molecular weight 70,000) across the BBB was 4.02% ± 0.57% relative to that of FITC-dextran without the BBB (blank) ( Figure 3D ). According to the previous studies, these researchers also used FITC-dextran (MW 70,000) as a paracellular marker to evaluate the permeability of this marker across the BBB model [30] [31] [32] . The BBB barrier integrity was thus verified based on the morphology, TEER, and permeability studies. 
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Cytotoxicity of Tween 80, GSH, RF, TAT, and Gefitinib on bEnd.3 and/or PC9 Cells
We tested the cytotoxicity of Tween 80, GSH, TAT, and RF on bEnd.3 cells by the sulforhodamine B (SRB) assay and found the concentrations of these compounds that maintained the viability of bEnd.3 cells over 90% (marked as #) were 400 µM, 0.5%, 36 and 9 µM, respectively ( Figure 4A-D) . Interestingly, more than 90% of bEnd.3 cells kept alive after treatment with gefitinib at 1 µM ( Figure  4E ). However, as we increased the concentrations of gefitinib to 10 µM, viability of bEnd.3 cells was significantly diminished to 60% ( Figure 4E ). Furthermore, we evaluated the cytotoxicity of gefitinib on PC9 cells and found that IC50 was 16.34 nM using a regression line for the plot with the linear scale 
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Cytotoxicity of Gefitinib in SUV-G, SUV-T, SUV-G+T across the BBB on PC9 Cells
The results showed that the direct cytotoxicity of 15 nM gefitinib on PC9 cells without the BBB (no bEnd.3 cells but with the empty transwell insert) decreased the viability of PC9 cells to 68.81% ± 3.20% ( Figure 5A ). The cytotoxic effect of gefitinib across the bEnd.3 cells on PC9 cells was dramatically reduced by existence of the BBB and thus the viability of PC9 cells returned to 90.22% ± 1.95% ( Figure 5A ). Gefitinib in the formulations of SUV, SUV-G, and SUV-T did not further improve the cytotoxicity of gefitinib ( Figure 5A ). However, gefitinib encapsulated in SUV-G+T across the BBB slightly diminished viability of PC9 cells more than that of free gefitinib or SUV (both p < 0.05; Figure 5A ). 
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Figure 5B). Here, maleimide (Mai) is a linker conjugated on the DSPE-PEG for binding to the SH group of TAT and RF. Nevertheless, SUV-RF (one novel cell penetrating peptide) across the BBB significantly further reduced viability of PC9 cells than that of free gefitinib or SUV-Mal (both p < 0.05; Figure 5B ). Gefitinib in free form or incorporated in SUV-Mal, SUV-TAT, or SUV-RF displayed no cytotoxicity to bEnd.3 cells ( Figure 5C ) and did not affect the TEER (Figure 6A ) of BBB model and permeability of sodium fluorescein across the bEnd.3 monolayer ( Figure 6B ). 2.6. Cytotoxicity of Gefitinib in SUV-Mal, SUV-TAT, or SUV-RF across the BBB on PC9 Cells
Similarly, gefitinib in the formulations of SUV-Mal and SUV-TAT (one well-known cell penetrating peptide) showed no significant difference from cytotoxicity of free gefitinib (both p > 0.05; Figure 5B ). Here, maleimide (Mai) is a linker conjugated on the DSPE-PEG for binding to the SH group of TAT and RF. Nevertheless, SUV-RF (one novel cell penetrating peptide) across the BBB significantly further reduced viability of PC9 cells than that of free gefitinib or SUV-Mal (both p < 0.05; Figure 5B ). Gefitinib in free form or incorporated in SUV-Mal, SUV-TAT, or SUV-RF displayed no cytotoxicity to bEnd.3 cells ( Figure 5C ) and did not affect the TEER (Figure 6A ) of BBB model and permeability of sodium fluorescein across the bEnd.3 monolayer ( Figure 6B 
Quantitative Analysis of Cellular Uptake and Transcytosis Mechanisms of SUV-RF
Because SUV-RF demonstrated the highest cytotoxicity across the BBB on PC9 cells among all the formulations used in this study, we thus chose this formulation for further investigation. The cellular uptake of coumarin-loaded SUV-Mal and SUV-RF by bEnd.3 cells was monitored by flow cytometer and confocal laser scanning microscope (CLSM), as exhibited in Figure 7 . After incubation of cells with SUV-Mal and SUV-RF for 0.5, 3, and 24 h, the mean fluorescence intensity of different treatment groups was normalized relatively to the value of SUV-Mal at 0.5 h. After 3 h uptake, relative fluorescence intensity of SUV-RF was significantly higher than that of SUV-Mal (p < 0.05; Figure 7A ). As treatment period was increased to 24 h, SUV-RF displayed more intracellular accumulation than that of SUV-Mal (p < 0.01; Figure 7A ). To investigate the mechanism underlying the intracellular uptake of SUVs, various endocytosis inhibitors were pretreated for 30 min to detect the internalization pattern of SUV-RF. When nystatin, an inhibitor of caveolae-mediated endocytosis was added, the relative uptake percentage was decreased to 85.87% ± 4.63% for SUV-RF, as demonstrated in Figure 7B . This indicated that the internalization of SUV-RF was partially mediated via caveolae-mediated transcytosis. Moreover, the pre-treatment of bEnd.3 cells by poly-lysine for 30 min before the addition of SUV-RF, an inhibitor of adsorptive transcytosis, the relative uptake percentage was further diminished to 30.91% ± 0.65% for SUV-RF ( Figure 7B ). This revealed that the cellular uptake of SUV-RF was mainly mediated through adsorptive transcytosis via electrostatic interaction between cationic RF and anionic membrane surface of bEnd.3 cells. In contrast, the uptake of SUV-RF had no significant difference before and after addition of 5-(N,N-Dimethyl) amiloride, an inhibitor of micropinocytosis, and chlorpromazine, an inhibitor of clathrin-mediated endocytosis, suggesting no involvement of micropinocytosis and clathrin-mediated endocytosis in the cellular uptake of SUV-RF across the bEnd.3 cells. 
Because SUV-RF demonstrated the highest cytotoxicity across the BBB on PC9 cells among all the formulations used in this study, we thus chose this formulation for further investigation. The cellular uptake of coumarin-loaded SUV-Mal and SUV-RF by bEnd.3 cells was monitored by flow cytometer and confocal laser scanning microscope (CLSM), as exhibited in Figure 7 . After incubation of cells with SUV-Mal and SUV-RF for 0.5, 3, and 24 h, the mean fluorescence intensity of different treatment groups was normalized relatively to the value of SUV-Mal at 0.5 h. After 3 h uptake, relative fluorescence intensity of SUV-RF was significantly higher than that of SUV-Mal (p < 0.05; Figure 7A ). As treatment period was increased to 24 h, SUV-RF displayed more intracellular accumulation than that of SUV-Mal (p < 0.01; Figure 7A ). To investigate the mechanism underlying the intracellular uptake of SUVs, various endocytosis inhibitors were pretreated for 30 min to detect the internalization pattern of SUV-RF. When nystatin, an inhibitor of caveolae-mediated endocytosis was added, the relative uptake percentage was decreased to 85.87% ± 4.63% for SUV-RF, as demonstrated in Figure 7B . This indicated that the internalization of SUV-RF was partially mediated via caveolae-mediated transcytosis. Moreover, the pre-treatment of bEnd.3 cells by poly-lysine for 30 min before the addition of SUV-RF, an inhibitor of adsorptive transcytosis, the relative uptake percentage was further diminished to 30.91% ± 0.65% for SUV-RF ( Figure 7B ). This revealed that the cellular uptake of SUV-RF was mainly mediated through adsorptive transcytosis via electrostatic interaction between cationic RF and anionic membrane surface of bEnd.3 cells. In contrast, the uptake of SUV-RF had no significant difference before and after addition of 5-(N,N-Dimethyl) amiloride, an inhibitor of micropinocytosis, and chlorpromazine, an inhibitor of clathrin-mediated endocytosis, suggesting no involvement of micropinocytosis and clathrin-mediated endocytosis in the cellular uptake of SUV-RF across the bEnd.3 cells.
The cellular uptake of coumarin-loaded SUV-Mal and SUV-RF by bEnd.3 cells was also verified by CLSM ( Figure 7C ). The cell nucleus was stained with 4′,6-diamidino-2-phenylindole (DAPI) (blue) for comparison. After incubation of cells with SUV-Mal or SUV-RF for 90 min, the green fluorescence, including green spots was concentrated and distributed around the cell nucleus. SUV-RF appeared to display intensely additional green fluorescence when compared to SUV-Mal after uptake of these two SUV for 90 min, separately ( Figure 7C ). The pretreatment of poly-lysine and nystatin inhibited the internalization of SUV-RF onto the bEnd.3 cells, especially signified by the lower accumulation of SUV-RF around the nucleus by the addition of poly-lysine ( Figure 7C ). This also supported the uptake mechanisms of SUV-RF via adsorptive-and caveolae-mediated transcytosis provided by the flow cytometric study ( Figure 7A,B) . 
Discussion
The major obstacle to treat BM is the limited penetration of chemotherapy across the bloodbrain barrier (BBB). Gefitinib, a first generation EGFR-TKI for treating NSCLC, has low cerebrospinal fluid-to-plasma ratio of about 0.3%-1.3% in patients with BM [3] . This limits the use of gefitinib in treating BM. We thus proposed to establish an in vitro model to mimic the BBB and confirmed the integrity of this BBB monolayer (Figure 3) . The nontoxic concentrations of compounds were screened on bEnd.3 cells (Figure 4) . We have designed liposomes with two different modifications: SUV-G+T and SUV-RF. The liposomal preparations demonstrated acceptable physicochemical characteristics (Figures 1 and 2 , Table 1) .
GSH receptors at the BBB interface offer an option in targeting these receptors by GSH-coated nanoparticles to escalate the active or passive transcytosis of therapeutic agents to the brain [12, 13] . GSH-PEGylated liposomes have been effectively applied as a brain drug delivery platform for the improvement of numerous treatments. One of the most developed GSH-liposomes is 2B3-101, which is PEGylated liposomal doxorubicin modified with GSH for the treatment of multiple brain cancer indications [15] . We have prepared liposomes with surface coating by GSH in this study. Moreover, The cellular uptake of coumarin-loaded SUV-Mal and SUV-RF by bEnd.3 cells was also verified by CLSM ( Figure 7C ). The cell nucleus was stained with 4 ,6-diamidino-2-phenylindole (DAPI) (blue) for comparison. After incubation of cells with SUV-Mal or SUV-RF for 90 min, the green fluorescence, including green spots was concentrated and distributed around the cell nucleus. SUV-RF appeared to display intensely additional green fluorescence when compared to SUV-Mal after uptake of these two SUV for 90 min, separately ( Figure 7C ). The pretreatment of poly-lysine and nystatin inhibited the internalization of SUV-RF onto the bEnd.3 cells, especially signified by the lower accumulation of SUV-RF around the nucleus by the addition of poly-lysine ( Figure 7C ). This also supported the uptake mechanisms of SUV-RF via adsorptive-and caveolae-mediated transcytosis provided by the flow cytometric study (Figure 7A,B) .
The major obstacle to treat BM is the limited penetration of chemotherapy across the blood-brain barrier (BBB). Gefitinib, a first generation EGFR-TKI for treating NSCLC, has low cerebrospinal fluid-to-plasma ratio of about 0.3%-1.3% in patients with BM [3] . This limits the use of gefitinib in treating BM. We thus proposed to establish an in vitro model to mimic the BBB and confirmed the integrity of this BBB monolayer (Figure 3) . The nontoxic concentrations of compounds were screened on bEnd.3 cells (Figure 4) . We have designed liposomes with two different modifications: SUV-G+T and SUV-RF. The liposomal preparations demonstrated acceptable physicochemical characteristics (Figures 1 and 2, Table 1) .
GSH receptors at the BBB interface offer an option in targeting these receptors by GSH-coated nanoparticles to escalate the active or passive transcytosis of therapeutic agents to the brain [12, 13] . GSH-PEGylated liposomes have been effectively applied as a brain drug delivery platform for the improvement of numerous treatments. One of the most developed GSH-liposomes is 2B3-101, which is PEGylated liposomal doxorubicin modified with GSH for the treatment of multiple brain cancer indications [15] . We have prepared liposomes with surface coating by GSH in this study. Moreover, liposomes were further modified with Tween 80 to evaluate their BBB penetration ability. Such a design has been found to cross the BBB by augmenting the plasma adsorption of apolipoprotein E or B on the nanoparticle surface for increasing binding to the low density lipoproteins (LDL) receptor [18] . Furthermore, nanoparticles modified with Tween 80 may circumvent P-gp transporters, thus intensifying uptake of nanoparticles across the BBB [19, 20] . In this study, our results mildly supported that gefitinib-encapsulated in liposomes modified with GSH and Tween 80 demonstrated greater cytotoxicity than that of free gefitinib or gefitinib-SUV (both p < 0.05; Figure 5A ). The concentrations of GSH and Tween 80 used in this study were nontoxic to bEnd.3 cells (Figure 4A,B) .
Another approach is to prepare liposomes with surface conjugation to RF for evaluating their BBB penetration effect. RF, a cell-penetrating peptide, possesses 17 amino acid residues and exhibits the structure of α-helix. This CPP bears six positive charges and has amphipathic property [27] . It has been reported that cationic α-helical CPP, including RF may interact with negatively charged extracellular glycosaminoglycans (GAGs) such as heparan sulfate (HS) via direct translocation and micropinocytosis [33] . The direct translocation is an endocytosis-independent process that the CPPs transport across the cell membrane via the barrel-stave model, inverted micelle model, or carpet model [34, 35] . RF bearing Arg and Phe displayed a greater capacity in binding to HS and causing HS-clustering, accounting for a superior cellular uptake ability via electrostatic and hydrophobic interactions when compared with peptides possessing Glu or Ala in HeLa and A549 cells [33] . RF also showed selective cytotoxicity to cancer cells, but exhibited lower cellular uptake into normal cells including mouse fibroblast 3T3-L1 in comparison to TAT [25, 33] . Our flow cytometric and CLSM results demonstrated that the endocytosis pathways of the uptake of SUV-RF into bEnd.3 cells was mainly through adsorptive transcytosis-mediated mechanism via electrostatic interaction of positively-charged Arg and Lys in RF with negatively charged glycoproteins of cell membrane and partially through caveolae-mediated transcytosis. Such PEGylated liposomes linked with RF showed efficacy to cross the BBB model to reduce the viability of PC-9 cells and displayed the advantage of low toxicity to bEnd.3 cells. The proposed schematic illustration of delivery of gefitinib-loaded PEGylated liposomes across the BBB is shown in Figure 8 . Figure 8 . 
Materials and Methods
Materials
Gefitinib was a kind gift or obtained from AstraZeneca, Alderley Park, UK or (AstraZeneca, Macclesfield, Cheshire, UK). RF with the amino acid sequence of GLKKLARLFHKLLKLGC was purchased from Kelowna Biotech (Taipei, Taiwan) at >95% purity. Cholesterol was purchased from Sigma-Aldrich (St. Louis, MO, USA). DSPC and DSPE-PEG2000-maleimide were obtained from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). All cell culture medium and reagents were bought 
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Materials
Gefitinib was a kind gift or obtained from AstraZeneca, Alderley Park, UK or (AstraZeneca, Macclesfield, Cheshire, UK). RF with the amino acid sequence of GLKKLARLFHKLLKLGC was purchased from Kelowna Biotech (Taipei, Taiwan) at >95% purity. Cholesterol was purchased from Sigma-Aldrich (St. Louis, MO, USA). DSPC and DSPE-PEG2000-maleimide were obtained from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). All cell culture medium and reagents were bought from Promega (Madison, WI, USA), Invitrogen (Carlsbad, CA, USA), Gibco BRL (Grand Island, NY, USA), or Hyclone (Logan, UT, USA). All other chemical reagents were obtained from either Merck (Darmstadt, Germany) or Sigma-Aldrich.
Preparation of PEGylated Liposomal Gefitinib-Formulations
DSPC, cholesterol, and DSPE-PEG-NH2 or DSPE-PEG-maleimide (for preparation of SUV-RF) were dissolved in chloroform and methanol (2:1). The resulting lipid solution was then dried using an evaporator. The lipid film was resuspended in 250 mM ammonium sulfate for 20 min under ultrasonication. The dispersion was extruded through a 0.1 µm membrane for four times. The product was ultrasonicated for 10 min. Gefitinib was loaded using dialysis against 500 mM sucrose and vortex for 1 h. The final gefitinib-containing liposomes were then dialyzed against pH 7.4 PBS.
The resultant liposomes were further reacted with RF at molar ratio of DSPE-PEG-maleimide: peptide (TAT or RF) = 1:1.5 for 24 h at room temperature. To obtain GSH or Tween 80 modification, liposomal solution was mixed with 0.84% GSH (w/v %) or 400 µM Tween 80. The mixture was ultrasonicated at room temperature for 30 min to allow a maximal GSH or Tween 80 modification. After GSH coating, the final liposomes were centrifuged at 15,000 rpm for 5 min (4 • C) through an Amicon Ultra-4 Centrifuge Filter (10,000 MWCO, Millipore Corp., Bedford, MA, USA). The supernatant was collected and the pH value was adjusted to 7.4. The above supernatant or GSH standard were then mixed with 6 mM Ellman's reagent (5,5 -dithiobis-2-nitrobenzoic acid (DTNB)). The absorbance of the formed yellow 5-thio-2-nitrobenzoic acid (TNB) proportional to total GSH concentration was measured at 412 nm at 25 • C using a Tecan Infinite 200 ® PRO multimode microplate reader (Männedorf, Switzerland). According to our calculation, the GSH coating percentage was 59.70%. Thus, the final concentration of GSH was determined to be 0.5% (w/v %). Descriptions of these liposomal formulations are demonstrated in Table 1 .
Characterization of PEGylated Liposomal Gefitinib-Formulations: Encapsulation Efficiency, Size Distribution, Zeta Potential, and Transmission Electron Microscopic Image
Unbound gefitinib was separated from the loaded liposomes by filtration and centrifugation. Gefitinib in the filtrate was analyzed by HPLC. A L7100 chromatography pump (Hitachi, Tokyo, Japan) equipped with an automated injector (Primaide 1210), a 5-µm Luna C18 liquid chromatography (LC) column (Phenomenex, Torrance, CA, USA) and an ultraviolet L2400 detector (Hitachi, Tokyo, Japan) was used for gefitinib analysis. The mobile phase was composed of 0.5% KH 2 PO 4 , acetonitrile, and methanol (55:25:20, v/v/v). The mixture was pre-degassed using a sonicator. The flow rate was 1 mL/min at room temperature. The peak area of gefitinib was calculated and compared with the calibration curve for quantitation. Each experiment was performed in quadruplicate.
EE% was calculated by the Equation (1) as shown below.
where W e is the weight of added gefitinib and W f is the weight of gefitinib in the filtrate. The size distribution and ζ potential of liposomes were measured using a Zetasizer Nano ZS90 (Malvern Instruments Ltd., Malvern, Worcestershire, UK) at 25 • C with a scattering angle of 90.0 • . Data was calculated by a cumulant method with Zetasizer family software v7.11 to obtain polydispersity index. Records were analyzed from four individual measurements.
The shape and particle morphology of SUV was observed under TEM. One drop of the sample solution was mounted onto a carbon-coated copper grid (300 mesh) for one minute at room temperature. The grid was air-dried at room temperature for five minutes. One drop of 1% phosphotungstic acid was then dripped onto the grid for five minutes. The preparation was air-dried for 30 min and then observed using a JEM 2000EX II transmission electron microscope (JEOL, Ltd., Tokyo, Japan) at 100 kV.
In Vitro Release of Gefitinib from SUV
Gefitinib release from SUV was measured using a dynamic release assay under sink conditions. An aliquot of each gefitinib formulation (1 mL) was put inside a dialysis bag and firmly wrapped. Then the dialysis bags were immersed in 500 mL of PBS in an incubator at 37 • C for 24 h with mild stirring at a rate of 100 rpm for maintaining a uniform drug concentration in the medium. At 1, 2, 4, 8, 12, and 24 h, the samples of 0.1 mL were removed and stored at −20 • C until analysis. With each sampling, the medium was replaced with pre-warmed PBS to maintain the total volume constant. The release of gefitinib from these preparations was sampled up to 24 h. The samples were centrifuged and the concentration of gefitinib in the collected supernatants was detected by HPLC. The cumulative gefitinib released percent was then determined. TEER was measured by a Millicell ERS-2 volt-ohm meter (Millipore Corp.) and a STX01 chopstick-style electrode (Millipore). To calculate TEER (Ω·cm 2 ), electrical resistance across a collagen IV-coated insert without cells (R blank ) was subtracted from the readings obtained on inserts with cells (R total ) and this value was multiplied by the surface area (A) of the insert (0.336 cm 2 ). The TEER of the cell monolayers was calculated according to the equation:
where R total is the resistance measured, R blank is resistance of control filters without cells and A is the surface area of filter (0.336 cm 2 ). After incubation, the upper wells with 100 µL of fresh serum-free medium containing 10 µg/mL of sodium fluorescein (376 Da; paracellular marker) or 0.09 mg/mL of fluorescein isothiocyanate-conjugated dextran (70 KDa FITC-dextran; paracellular marker) were inserted into new lower wells containing 0.6 mL of fresh serum-free medium. After incubation in the dark at 37 • C for 1 h, 50 µL of the lower well media was sampled, and fluorescence intensity of sodium fluorescein or FITC-dextran was measured with excitation at 460 and 494 nm and emission at 515 and 521 nm, respectively, using a Tecan microplate reader. The relative permeability changes were calculated corresponding to coated inserts without cells, which represented a reference for maximal permeability [36] . 
Cell Viability by the SRB Assay
After overnight seeding of PC-9 and bEnd.3 cells in 96-well flat-bottomed plates at density of 4 × 10 3 cells/well and 8 × 10 3 cells/well, different concentrations of gefitinib were added in the culture medium for the indicated time. The cytotoxic effects were determined by sulforhodamine B assay [37] . Cell viability was determined by dividing the absorbance values of treated cells to that of cells of medium control.
Endocytic Uptake Mechanisms of SUV-RF
bEnd.3 cells were pre-treated with various endocytosis inhibitors, such as chlopromazine hydrochloride (CPZ; 10 µM, clathrin-mediated endocytosis inhibitor), 5-(N,N-dimethyl) amiloride hydrochloride (DMA; 20 µg/mL, micropinocytosis inhibitor), nystatin (Nys; 10 µg/mL, caveolae-mediated endocytosis inhibitor) and poly-lysine (PL; 250 µg/mL, inhibitor of adsorptive transcytosis) for 30 min and then incubated with coumarin-6-loaded SUV-RF for 90 min [38] . Two methods including flow cytometry and confocal laser scanning microscope (CLSM) were used to detect the relative fluorescence intensity and uptake images of internalized coumarin-6-loaded SUV-RF after treatment of different transcytosis inhibitors. For flow cytometric analysis, after incubation of cells with SUV-Mal and SUV-RF for 0.5, 3, and 24 h, the cells were detached by Accumax, collected, and suspended in PBS at 37 • C. Flow cytometric analysis was then carried out using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) equipped with an argon ion laser and operated at 488 nm. Fluorescence was measured through a 520 nm FL1 filter (515-545 nm) for coumarin-6 and fluorescence signals were collected on a logarithmic scale. Data acquisition and analysis were performed using commercial BD FACStation™ software (BD Biosciences). At least 10,000 cells were analyzed in each sample. Within each experiment, determinations were performed in triplicate.
Intracellular Uptake of SUV-RF by Confocal Laser Scanning Microscope (CLSM)
After treatment with various transcytosis inhibitors for 30 min, the cells were further incubated with coumarin-6 (in green)-loaded SUV-RF at 37 • C for 90 min. The cells were then rinsed using PBS. The images were taken using a confocal laser-scanning microscope (Olympus FV10i, Olympus America Inc., Center Valley, PA, USA) with excitation at 490 nm and emission at 520 nm. The cells were also stained with DAPI (in blue) in the nucleus for comparison. At least 3 photos were taken in each sample. The representative image of each treatment is exhibited.
Statistical Analysis
Experimental data were analyzed by Student s t-test and expressed as the mean ± SEM. Statistical significance was set at p < 0.05.
Conclusions
Taken together, cell selective CPP-conjugated SUV-RF shed light on improving gefitinib delivery across the BBB via modulating the transcytosis pathway(s). We expect that gefitinib loaded SUV-RF will potentially become a more promising brain delivery platform due to their ability to increase penetration across the BBB and enhance targeting to the tumor cells. This liposomal formulation may reduce the off-target side effects to normal brain cells. The special and serious situation of brain metastases highlights the necessity for a multifunctional approach integrating an effective delivery system to carry gefitinib as a potential nanomedicine to enhance the clinical efficacy of target therapy.
